资源类型

期刊论文 192

年份

2024 6

2023 21

2022 18

2021 23

2020 5

2019 17

2018 13

2017 6

2016 13

2015 9

2014 8

2013 8

2012 13

2011 7

2010 7

2009 10

2008 1

2007 2

2000 2

展开 ︾

关键词

癌症 6

结直肠癌 4

肺癌 3

肿瘤 3

临床试验 2

乳腺癌 2

人工智能 2

免疫疗法 2

外泌体 2

糖基化 2

糖尿病 2

肿瘤微环境 2

诊断 2

调节性T细胞 2

BNCT 1

Beclin-1 1

CD44 1

HIFU 1

MCF-7细胞球 1

展开 ︾

检索范围:

排序: 展示方式:

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

《医学前沿(英文)》 2011年 第5卷 第4期   页码 323-332 doi: 10.1007/s11684-011-0172-4

摘要:

Emerging immunological strategies: recent advances and future directions

《医学前沿(英文)》 2021年 第15卷 第6期   页码 805-828 doi: 10.1007/s11684-021-0886-x

摘要: Immunotherapy plays a compelling role in cancer treatment and has already made remarkable progress. However, many patients receiving immune checkpoint inhibitors fail to achieve clinical benefits, and the response rates vary among tumor types. New approaches that promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodies, chimeric antigen receptor T cell products, and cancer vaccines. Small molecule drugs include agonists and inhibitors that can reach the intracellular or extracellular targets of immune cells participating in innate or adaptive immune pathways. Bispecific antibodies, which bind two different antigens or one antigen with two different epitopes, are of great interest. Chimeric antigen receptor T cell products and cancer vaccines have also been investigated. This review explores the recent progress and challenges of different forms of immunotherapy agents and provides an insight into future immunotherapeutic strategies.

关键词: cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer vaccines    

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

《医学前沿(英文)》 2007年 第1卷 第1期   页码 11-19 doi: 10.1007/s11684-007-0003-9

摘要: A remarkable advance in tumor immunology during the last decade is the elucidation of the antigenic basis of tumor recognition and destruction. A variety of tumor antigens have been identified using several strategies including conventional experiments and newly developed bioinformatics. Among these antigens, cancer/testis antigen (CT antigen) is considered to be the most promising target for immunotherapy by vaccination. Successful immunotherapy of tumors requires understanding of the natural relationship between the immune system and tumor in the status of differentiation, invasion and maturation. Continued progress in development of effective cancer vaccines depends on the identification of appropriate target antigens, the establishment of optimal immunization strategies without harmful autoimmune responses and the ability of manipulating tumor microenvironment to circumvent immune suppression and to augment the anti-tumor immune response.

关键词: development     conventional     identification     elucidation     Successful immunotherapy    

新冠病毒变异株——新型mRNA疫苗能否经受挑战?

Jennifer Welsh

《工程(英文)》 2021年 第7卷 第6期   页码 712-714 doi: 10.1016/j.eng.2021.04.005

Universal influenza virus vaccines: what can we learn from the human immune response following exposure

null

《医学前沿(英文)》 2017年 第11卷 第4期   页码 471-479 doi: 10.1007/s11684-017-0602-z

摘要:

Several universal influenza virus vaccine candidates based on eliciting antibodies against the hemagglutinin stalk domain are in development. Typically, these vaccines induce responses that target group 1 or group 2 hemagglutinins with little to no cross-group reactivity and protection. Similarly, the majority of human anti-stalk monoclonal antibodies that have been isolated are directed against group 1 or group 2 hemagglutinins with very few that bind to hemagglutinins of both groups. Here we review what is known about the human humoral immune response to vaccination and infection with H7 subtype influenza viruses on a polyclonal and monoclonal level. It seems that unlike vaccination with H5 hemagglutinin, which induces antibody responses mostly restricted to the group 1 stalk domain, H7 exposure induces both group 2 and cross-group antibody responses. A better understanding of this phenomenon and the underlying mechanisms might help to develop future universal influenza virus vaccine candidates.

关键词: universal influenza virus vaccine     hemagglutinin stalk     H7N9    

核酸疫苗研发态势与发展建议

李爱花,杨雪梅,孙轶楠,苑亚坤,杨俊涛

《中国工程科学》 2021年 第23卷 第4期   页码 153-161 doi: 10.15302/J-SSCAE-2021.04.018

摘要:

应对新型冠状病毒肺炎(COVID-19)疫情防控的迫切需求,核酸疫苗以其快速高效的优点得到了疫苗研发领域的高度重视,特别是信使核糖核酸(mRNA)疫苗的研发进程显著加快,首次获批上市并在人体中使用。本文从核酸疫苗及相关技术概念、研发轨迹与发展趋势等方面总结梳理核酸疫苗的研发态势,辨识核酸疫苗特征,分析 COVID-19 疫情对 mRNA疫苗研究的促进作用,梳理核酸疫苗拓展应用的主要领域,针对可能存在的技术性、安全性问题开展深入讨论。研究建议,从改良目的基因表达、完善递送系统、提高免疫应答、增强 mRNA 稳定性及易存性等方面着手,着力开展核酸疫苗的关键技术开发;严格监管核酸疫苗的安全性和有效性;引导利益相关方对具有安全性风险、可能对肿瘤与传染病防控带来颠覆性影响的 mRNA 疫苗技术开展改进研究,注重技术研发的前瞻布局并促进应用转化。

关键词: 核酸疫苗     脱氧核糖核酸(DNA)疫苗     核糖核酸(RNA)疫苗     信使核糖核酸(mRNA)疫苗     新型冠状病毒肺 炎     肿瘤    

Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression

《医学前沿(英文)》 2024年 第18卷 第3期   页码 430-445 doi: 10.1007/s11684-023-1049-z

摘要: Crosstalk between cancer cells and the immune microenvironment is determinant for liver cancer progression. A tumor subpopulation called liver cancer stem cells (CSCs) significantly accounts for the initiation, metastasis, therapeutic resistance, and recurrence of liver cancer. Emerging evidence demonstrates that the interaction between liver CSCs and immune cells plays a crucial role in shaping an immunosuppressive microenvironment and determining immunotherapy responses. This review sheds light on the bidirectional crosstalk between liver CSCs and immune cells for liver cancer progression, as well as the underlying molecular mechanisms after presenting an overview of liver CSCs characteristic and their microenvironment. Finally, we discuss the potential application of liver CSCs-targeted immunotherapy for liver cancer treatment.

关键词: liver cancer     cancer stem cell     immune cell     immunotherapy    

A review of the safety and efficacy of current COVID-19 vaccines

《医学前沿(英文)》 2022年 第16卷 第1期   页码 39-55 doi: 10.1007/s11684-021-0893-y

摘要: Vaccination is the most effective and feasible way to contain the coronavirus disease 2019 (COVID-19) pandemic. The rapid development of effective COVID-19 vaccines is an extraordinary achievement. This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccines and discussed the challenges and prospects of the vaccine-based approaches in a global crisis. Overall, most of the current vaccines have shown safety and efficacy/effectiveness during actual clinical trials or in the real-world studies, indicating a development of pandemic control. However, many challenges are faced by pandemic control in terms of maximizing the effect of vaccines, such as rapid vaccine coverage, strategies to address variants with immune escape capability, and surveillance of vaccine safety in the medium- and long-terms.

关键词: COVID-19     SARS-CoV-2     vaccine     safety     efficacy     effectiveness     immunogenicity    

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer

《医学前沿(英文)》 2021年 第15卷 第6期   页码 942-942 doi: 10.1007/s11684-021-0876-z

Progress and challenges in RET-targeted cancer therapy

《医学前沿(英文)》 2023年 第17卷 第2期   页码 207-219 doi: 10.1007/s11684-023-0985-y

摘要: The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.

关键词: pralsetinib     selpercatinib     RET-alteration     lung cancer     thyroid cancer     tumor-agnostic therapy     drug resistance    

Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

Yun Zhang, Robert A. Weinberg

《医学前沿(英文)》 2018年 第12卷 第4期   页码 361-373 doi: 10.1007/s11684-018-0656-6

摘要:

The cell-biological program termed the epithelial-to-mesenchymal transition (EMT) plays an important role in both development and cancer progression. Depending on the contextual signals and intracellular gene circuits of a particular cell, this program can drive fully epithelial cells to enter into a series of phenotypic states arrayed along the epithelial-mesenchymal phenotypic axis. These cell states display distinctive cellular characteristics, including stemness, invasiveness, drug-resistance and the ability to form metastases at distant organs, and thereby contribute to cancer metastasis and relapse. Currently we still lack a coherent overview of the molecular and biochemical mechanisms inducing cells to enter various states along the epithelial-mesenchymal phenotypic spectrum. An improved understanding of the dynamic and plastic nature of the EMT program has the potential to yield novel therapies targeting this cellular program that may aid in the management of high-grade malignancies.

关键词: epithelial-to-mesenchymal transition     cancer     metastasis     cancer stem cell    

Metformin for cancer prevention

Yonghua Yang

《医学前沿(英文)》 2011年 第5卷 第2期   页码 115-117 doi: 10.1007/s11684-011-0112-3

Orlistat induces ferroptosis-like cell death of lung cancer cells

《医学前沿(英文)》 2021年 第15卷 第6期   页码 922-932 doi: 10.1007/s11684-020-0804-7

摘要: Aberrant de novo lipid synthesis is involved in the progression and treatment resistance of many types of cancers, including lung cancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need. In this study, we tested the anticancer activity of orlistat, an FDA-approved anti-obesity drug, in human and mouse cancer cells in vitro and in vivo, and we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lung cancer cells and induced ferroptosis-like cell death in vitro. Mechanistically, we found that orlistat reduced the expression of GPX4, a central ferroptosis regulator, and induced lipid peroxidation. In addition, we systemically analyzed the genome-wide gene expression changes affected by orlistat treatment using RNA-seq and identified FAF2, a molecule regulating the lipid droplet homeostasis, as a novel target of orlistat. Moreover, in a mouse xenograft model, orlistat significantly inhibited tumor growth and reduced the tumor volumes compared with vehicle control (P<0.05). Our study showed a novel mechanism of the anticancer activity of orlistat and provided the rationale for repurposing this drug for the treatment of lung cancer and other types of cancer.

关键词: orlistat     ferroptosis     FAF2     lung cancer    

Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance

null

《医学前沿(英文)》 2012年 第6卷 第4期   页码 376-380 doi: 10.1007/s11684-012-0228-0

摘要:

The forkhead transcription factors FOXO and FOXM1 have pivotal roles in tumorigenesis and in mediating chemotherapy sensitivity and resistance. Recent research shows that the forkhead transcription factor FOXM1 is a direct transcriptional target repressed by the forkhead protein FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling pathway. Intriguingly, FOXM1 and FOXO3a also compete for binding to the same gene targets, which have a role in chemotherapeutic drug action and sensitivity. An understanding of the role and regulation of the FOXO-FOXM1 axis will impact directly on our knowledge of chemotherapeutic drug action and resistance in patients, and provide new insights into the design of novel therapeutic strategy and reliable biomarkers for prediction of drug sensitivity.

关键词: FOXO3a     FOXM1     transcription factor     cancer     drug resistance     tumorigenesis    

Low-dose CT for lung cancer screening: opportunities and challenges

null

《医学前沿(英文)》 2018年 第12卷 第1期   页码 116-121 doi: 10.1007/s11684-017-0600-1

摘要:

Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancer death in both males and females. Screening for lung cancer coupled with earlier intervention has long been studied as an approach to mortality reduction. However, minimal progress was achieved until recently, when low-dose spiral computed tomography (LDCT) screening demonstrated a 20% reduction in mortality from lung cancer in a randomized controlled trial (RCT), the National Lung Screening Trial, from the United States. On the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populations by several clinical guidelines. However, results from the following independent RCTs in Europe failed to show consistent conclusions. In addition, intractable problems gradually emerged with the progress of LDCT screening. This paper summarizes and discusses the main observations and challenges of LDCT screening for lung cancer. Before spreading implementation of LDCT screening, challenges, including high false-positive rates, overdiagnosis, enormous costs, and radiation risk, must be addressed. Complementary biomarkers and technical improvement are expected in the field of lung cancer screening in the near future.

关键词: lung cancer     low-dose computerized tomography     early detection     opportunities     challenges    

标题 作者 时间 类型 操作

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

期刊论文

Emerging immunological strategies: recent advances and future directions

期刊论文

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

期刊论文

新冠病毒变异株——新型mRNA疫苗能否经受挑战?

Jennifer Welsh

期刊论文

Universal influenza virus vaccines: what can we learn from the human immune response following exposure

null

期刊论文

核酸疫苗研发态势与发展建议

李爱花,杨雪梅,孙轶楠,苑亚坤,杨俊涛

期刊论文

Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression

期刊论文

A review of the safety and efficacy of current COVID-19 vaccines

期刊论文

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer

期刊论文

Progress and challenges in RET-targeted cancer therapy

期刊论文

Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

Yun Zhang, Robert A. Weinberg

期刊论文

Metformin for cancer prevention

Yonghua Yang

期刊论文

Orlistat induces ferroptosis-like cell death of lung cancer cells

期刊论文

Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance

null

期刊论文

Low-dose CT for lung cancer screening: opportunities and challenges

null

期刊论文